HROW
Harrow Health, Inc.
HROW's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over HROW overall, supported by lower modeled downside and stronger modeled upside.
HROW Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Weak |
HROW's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HROW PE Valuation
HROW has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 26x next year's earnings.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HROW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
HROW has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.10 | — |
| Q3 2026 | -$0.75 | -$0.60 |
| Q2 2026 | -$0.97 | -$0.67 |
| Q1 2026 | -$0.38 | +$0.23 |
| Q4 2025 | -$0.14 | +$0.35 |
| Q3 2025 | -$0.15 | +$0.79 |
| Q2 2025 | -$0.30 | +$0.65 |
| Q1 2025 | -$0.61 | +$0.30 |
| Q4 2024 | -$0.49 | +$0.26 |
HROW lost $0.75 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over HROW on earnings quality, reporting a profit while its opponent remains loss making.
HROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $99.3M | +39% |
| Q2 2026 | $70.7M | +11% |
| Q1 2026 | $44.2M | -7.6% |
| Q4 2025 | $89.1M | +33% |
| Q3 2025 | $71.6M | +45% |
| Q2 2025 | $63.7M | +30% |
| Q1 2025 | $47.8M | +38% |
| Q4 2024 | $66.8M | +84% |
HROW has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -9 points |
| Q2 2026 | -16% | -34 points |
| Q1 2026 | -50% | -27 points |
| Q4 2025 | 18% | -1.8 points |
| Q3 2025 | 21% | +18 points |
| Q2 2025 | 18% | +15 points |
| Q1 2025 | -23% | -3.4 points |
| Q4 2024 | 19% | +33 points |
HROW has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
HROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9M | -155% |
| Q2 2026 | -$10.2M | -$9.3M |
| Q1 2026 | -$9.2M | -147% |
| Q4 2025 | $8.1M | +$26.4M |
| Q3 2025 | $16.4M | +598% |
| Q2 2025 | -$969K | +$2.1M |
| Q1 2025 | $19.5M | +$24.2M |
| Q4 2024 | -$18.3M | -316% |
HROW's free cash flow was −$20M over the past year, against $17M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over HROW on cash generation, producing positive trailing cash flow while its opponent burns cash.
HROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.2M shares |
| 1 year | -0.9% | -341K shares |
| 3 years | +12% | +4.3M shares |
| 5 years | +42% | +11.4M shares |
| Available history | +46% | +12.1M shares |
HROW has the edge over UNH on shareholder dilution, with a more favorable share count trend.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
HROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 9.7x | High |
| Q4 2025 | 5.5x | High |
| Q3 2025 | 9.3x | High |
| Q2 2025 | 12.2x | High |
| Q1 2025 | 29.7x | High |
| Q4 2024 | 20.2x | High |
| Q4 2023 | 88.0x | High |
| Q3 2023 | 37.2x | High |
HROW's net debt is about 9.7 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
HROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.2 | Neutral |
| Stochastic | 9.8 | Oversold |
HROW's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
HROW PE vs Healthcare Sector
| Metric | HROW | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HROW has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
HROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.0 | 2.4% below |
| 20 week MA | $35.3 | 20% below |
| 50 week MA | $39.0 | 27% below |
| 100 week MA | $36.1 | 21% below |
| 200 week MA | $28.8 | 1.6% below |
HROW is in a downtrend: it's below all five of its weekly moving averages, and 1.6% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over HROW on trend strength, trading above more of its moving averages.
HROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.88 | $5.78 | -27% |
| 2021 | $5.78 | $9.20 | +59% |
| 2022 | $9.20 | $14.2 | +54% |
| 2023 | $14.2 | $11.2 | -21% |
| 2024 | $11.2 | $33.5 | +199% |
| 2025 | $33.5 | $50.1 | +50% |
| 2026 YTD | $50.1 | $28.3 | -44% |
HROW is down 44% so far in 2026, after finishing higher in four of the previous six years.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over HROW on returns for 2026, with the stronger performance.